Cidara Therapeutics: Rezafungin Data Could Bring Value

Jul. 20, 2021 5:33 AM ETCidara Therapeutics, Inc. (CDTX)10 Comments
William Meyers profile picture
William Meyers


  • Cidara is in clinical trials with a fungus therapy and has an antiviral platform.
  • Its stock price is at rock bottom.
  • Rezafungin latest data update is encouraging, with an FDA submission likely in 2022.
Candida auris fungi, emerging multidrug resistant fungus
Dr_Microbe/iStock via Getty Images

Cidara Therapeutics (NASDAQ:CDTX) has fallen into the microcap category, sporting a market cap of just $77 million at $1.58 per share in the morning on July 19. That is down from a 52-week high of $4.34, and a much more optimistic past. It went over $15 per

This article was written by

William Meyers profile picture
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.

Disclosure: I/we have a beneficial long position in the shares of CDTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: CDTX represents less than 0.1% of my portfolio. I intend to accumulate more.

Recommended For You

Comments (10)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.